2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2779

Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience
Abstract Number: 2780

Relationship Between Immunogenicity, Hypersensitivity Reactions and Skin Tests Against Infliximab, Etanercept and Adalimumab in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Abstract Number: 2781

Absence of Effects of Filgotinib on Erythrocytes, CD8+ and NK Cells in Rheumatoid Arthritis Patients Brings Further Evidence for the JAK1 Selectivity of Filgotinib
Abstract Number: 2782

Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis
Abstract Number: 2783

What Is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort
Abstract Number: 2784

Faecal Levels of Calprotectin Are Increased in Patients with Primary Sjögren’s Syndrome and Correlates with Disease Activity
Abstract Number: 2785

Association of Anti-Glutamate Receptor Subunit NR2 Antibody and Psychiatric Disorder in Patients with Primary Sjögren Syndrome
Abstract Number: 2786

miR200b-5p: A Possible Predictor of Lymphoma Development in Sjögren’s Syndrome (SS)?
Abstract Number: 2787

Expression of Interferons Lambda in Salivary Glands of Patients with Sjögren’s Syndrome
Abstract Number: 2788

DNA Microarray Analysis of Labial Salivary Glands in Patients with Sjögren’s Syndrome: Comparison with IgG4-Related Disease
Abstract Number: 2789

Blood and Salivary Gland BAFF-Driven B-Cell Hyperactivity in Rituximab Non-Responder Patients with Primary Sjögren’s Syndrome
Abstract Number: 2790

Leflunomide/Hydroxychoroquine Combination Treatment Additively Inhibits T Cell Receptor/Toll-like Receptor 9-Triggered Th1 and Th17 Cytokine Secretion
Abstract Number: 2791

TREX-1 Variants in Sjögren’s Syndrome Related Lymphomagenesis
Abstract Number: 2792

Not Only Sjögren’s Syndrome. EBV Infection Reactivation As a Risk Factor of the Dryness Symptome Development
Abstract Number: 2793

IL35 Serum Level Is Decreased in Patients with Primary Sjogren Syndrome, Essentially in Patients with the More Active Disease Data from the French Prospective Assess Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].